{
    "eid": "2-s2.0-85116718584",
    "title": "Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study",
    "cover-date": "2021-10-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Gastroenterology",
            "@code": "2715",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Milind Javle",
        "Sameek Roychowdhury",
        "Robin Kate Kelley",
        "Saeed Sadeghi",
        "Teresa Macarulla",
        "Karl Heinz Weiss",
        "Dirk Thomas Waldschmidt",
        "Lipika Goyal",
        "Ivan Borbath",
        "Anthony El-Khoueiry",
        "Mitesh J. Borad",
        "Wei Peng Yong",
        "Philip A. Philip",
        "Michael Bitzer",
        "Surbpong Tanasanvimon",
        "Ai Li",
        "Amit Pande",
        "Harris S. Soifer",
        "Stacie Peacock Shepherd",
        "Susan Moran",
        "Andrew X. Zhu",
        "Tanios S. Bekaii-Saab",
        "Ghassan K. Abou-Alfa"
    ],
    "citedby-count": 138,
    "ref-count": 35,
    "ref-list": [
        "Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states",
        "Cholangiocarcinoma 2020: the next horizon in mechanisms and management",
        "Epidemiology of cholangiocarcinoma; United States incidence and mortality trends",
        "Key statistics for bile duct cancer",
        "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer",
        "NCCN guidelines version 5.2021. Hepatobiliary cancers",
        "Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial",
        "Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes",
        "Biliary cancer: utility of next-generation sequencing for clinical management",
        "Genomic spectra of biliary tract cancer",
        "Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma",
        "Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations",
        "Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles",
        "Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma",
        "SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: a retrospective analysis",
        "Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma",
        "Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma",
        "Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers",
        "Erdafitinib in locally advanced or metastatic urothelial carcinoma",
        "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study",
        "FDA grants breakthrough therapy designation for Taiho Oncology's futibatinib for treatment of advanced cholangiocarcinoma",
        "Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase",
        "FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor",
        "Evaluation of BGJ398, a fibroblast growth factor receptor 1\u20133 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study",
        "Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma",
        "Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions",
        "Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems",
        "Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis",
        "116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harbouring FGFR2 fusions/rearrangements: FOENIX-CCA2",
        "Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations",
        "Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines",
        "Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor",
        "Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1\u20133 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3-altered advanced/metastatic urothelial carcinoma",
        "Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer",
        "First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma"
    ],
    "affiliation": [
        {
            "affiliation-city": "Scottsdale",
            "@id": "60026952",
            "affilname": "Mayo Clinic Scottsdale-Phoenix, Arizona",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026952",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Tubingen",
            "@id": "60017246",
            "affilname": "Eberhard Karls Universit\u00e4t T\u00fcbingen",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017246",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60008130",
            "affilname": "Massachusetts General Hospital Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008130",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Columbus",
            "@id": "60002058",
            "affilname": "The Ohio State University Comprehensive Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002058",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "San Francisco",
            "@id": "122213671",
            "affilname": "QED Therapeutics",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122213671",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "60108904",
            "affilname": "Fudan University Shanghai Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60108904",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60106366",
            "affilname": "National University Health System",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60106366",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60106362",
            "affilname": "Cancer Science Institute of Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60106362",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Heidelberg",
            "@id": "60082880",
            "affilname": "Krankenhaus Salem",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082880",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Detroit",
            "@id": "60033199",
            "affilname": "Barbara Ann Karmanos Cancer Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033199",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "San Francisco",
            "@id": "60029881",
            "affilname": "UCSF Helen Diller Family Comprehensive Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029881",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Los Angeles",
            "@id": "60022143",
            "affilname": "USC Norris Comprehensive Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022143",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Houston",
            "@id": "60015023",
            "affilname": "The University of Texas MD Anderson Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015023",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Brussels",
            "@id": "60012936",
            "affilname": "Cliniques Universitaires Saint-Luc",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012936",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Barcelona",
            "@id": "60012486",
            "affilname": "Hospital Universitari Vall d'Hebron",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012486",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Koln",
            "@id": "60008658",
            "affilname": "Uniklinik K\u00f6ln",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008658",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Los Angeles",
            "@id": "60005247",
            "affilname": "David Geffen School of Medicine at UCLA",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005247",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Heidelberg",
            "@id": "60003280",
            "affilname": "Universit\u00e4tsklinikum Heidelberg",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60003280",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "San Francisco",
            "@id": "100822091",
            "affilname": "Clinical Development",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100822091",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Bayer Health Pharma",
        "CytomX",
        "Falk",
        "Halozyme Pharmaceuticals",
        "Incyte",
        "QED Therapeutics",
        "Senhwa Pharmaceuticals",
        "Shire Baxalta",
        "Bristol Myers Squibb",
        "AstraZeneca",
        "Genentech",
        "Merck",
        "Novartis",
        "Roche",
        "Gilead",
        "Celgene",
        "Novartis",
        "Exelixis",
        "G1 Therapeutics",
        "Ipsen",
        "Eisai",
        "Servier"
    ]
}